ÂÜÀòÂÒÂ×

John Petersen is currently the VP CMC at Glyscend Therapeutics since March 2020. With extensive experience in the pharmaceutical industry, John has also worked as a Principal at Petersen Consulting since May 2015, providing consulting services in various areas including R&D, pharmaceutical CMC, IP evaluation, and strategic program evaluation. Prior to their current role, John has held significant positions at companies such as Akebia Therapeutics, SynDevRx, and Genzyme, demonstrating a strong background in chemistry and manufacturing. John holds a PhD in Chemistry from the University of California, Berkeley, and a BS in Chemistry from Massachusetts Institute of Technology.